vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $62.1M, roughly 1.2× Cytek Biosciences, Inc.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -70.9%, a 110.8% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 4.0%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -4.6%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
ARI vs CTKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $62.1M |
| Net Profit | $29.2M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | 39.7% | -9.0% |
| Net Margin | 39.9% | -70.9% |
| Revenue YoY | 4.0% | 8.1% |
| Net Profit YoY | -28.2% | -557.1% |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | $62.1M | ||
| Q3 25 | $61.6M | $52.3M | ||
| Q2 25 | $70.9M | $45.6M | ||
| Q1 25 | $65.8M | $41.5M | ||
| Q4 24 | $70.5M | $57.5M | ||
| Q3 24 | $71.6M | $51.5M | ||
| Q2 24 | $81.1M | $46.6M | ||
| Q1 24 | $80.5M | $44.9M |
| Q4 25 | $29.2M | $-44.1M | ||
| Q3 25 | $50.8M | $-5.5M | ||
| Q2 25 | $20.7M | $-5.6M | ||
| Q1 25 | $26.0M | $-11.4M | ||
| Q4 24 | $40.7M | $9.6M | ||
| Q3 24 | $-91.5M | $941.0K | ||
| Q2 24 | $35.8M | $-10.4M | ||
| Q1 24 | $-104.5M | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
| Q4 25 | 39.7% | -9.0% | ||
| Q3 25 | 82.8% | -17.6% | ||
| Q2 25 | 29.4% | -23.3% | ||
| Q1 25 | 39.7% | -36.1% | ||
| Q4 24 | 57.9% | 5.2% | ||
| Q3 24 | -127.8% | -8.2% | ||
| Q2 24 | 44.2% | -18.3% | ||
| Q1 24 | -129.6% | -23.9% |
| Q4 25 | 39.9% | -70.9% | ||
| Q3 25 | 82.4% | -10.5% | ||
| Q2 25 | 29.3% | -12.2% | ||
| Q1 25 | 39.5% | -27.5% | ||
| Q4 24 | 57.7% | 16.8% | ||
| Q3 24 | -127.9% | 1.8% | ||
| Q2 24 | 44.1% | -22.4% | ||
| Q1 24 | -129.8% | -13.8% |
| Q4 25 | $0.19 | — | ||
| Q3 25 | $0.34 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $-0.69 | — | ||
| Q2 24 | $0.23 | — | ||
| Q1 24 | $-0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $90.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $341.7M |
| Total Assets | $9.9B | $461.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | $90.9M | ||
| Q3 25 | $245.9M | $93.3M | ||
| Q2 25 | $177.6M | $75.5M | ||
| Q1 25 | $166.4M | $95.3M | ||
| Q4 24 | $317.4M | $98.7M | ||
| Q3 24 | $194.3M | $162.3M | ||
| Q2 24 | $174.7M | $177.9M | ||
| Q1 24 | $161.2M | $168.8M |
| Q4 25 | $1.9B | $341.7M | ||
| Q3 25 | $1.9B | $378.6M | ||
| Q2 25 | $1.8B | $377.6M | ||
| Q1 25 | $1.9B | $379.6M | ||
| Q4 24 | $1.9B | $395.7M | ||
| Q3 24 | $1.9B | $385.5M | ||
| Q2 24 | $2.0B | $389.1M | ||
| Q1 24 | $2.0B | $392.6M |
| Q4 25 | $9.9B | $461.5M | ||
| Q3 25 | $9.5B | $494.9M | ||
| Q2 25 | $9.8B | $493.3M | ||
| Q1 25 | $8.8B | $482.6M | ||
| Q4 24 | $8.4B | $499.5M | ||
| Q3 24 | $9.1B | $491.2M | ||
| Q2 24 | $9.3B | $483.7M | ||
| Q1 24 | $9.2B | $492.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 4.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | $-771.0K | ||
| Q3 25 | $31.7M | $-3.9M | ||
| Q2 25 | $63.2M | $108.0K | ||
| Q1 25 | $39.3M | $-125.0K | ||
| Q4 24 | $200.3M | $2.0M | ||
| Q3 24 | $47.2M | $13.2M | ||
| Q2 24 | $50.2M | $6.2M | ||
| Q1 24 | $52.8M | $4.0M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-974.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -2.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | — | ||
| Q2 25 | 3.05× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 4.93× | 0.21× | ||
| Q3 24 | — | 14.05× | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARI
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
